Velpatasvir
Showing 26 - 50 of 109
SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients
Recruiting
- Hepatitis C
- Epclusa (sofosbuvir and velpatasvir)
-
Guangzhou, Guangdong, ChinaDeparment of Infectious Diseases, the Second Affiliated Hospital
Jul 1, 2021
Hepatitis C, Transplantation Disease Transmission Trial in United States (Sofosbuvir/Velpatasvir,
Completed
- Hepatitis C
- Transplantation Disease Transmission
-
San Francisco, California
- +5 more
Feb 10, 2021
Kidney Transplant, Hepatitis C, HCV Trial in Columbus (Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir
Completed
- Kidney Transplant
- +2 more
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
- Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
-
Columbus, OhioBrenda Cuson
Jul 29, 2021
Hepatitis C Trial in Worldwide (SOF/VEL for 6 weeks, SOF/VEL for 12 weeks)
Completed
- Hepatitis C
- SOF/VEL for 6 weeks
- SOF/VEL for 12 weeks
-
Baltimore, Maryland
- +24 more
Nov 22, 2021
HCV Infection Trial in Christchurch (SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol)
Chronic Hepatitis C Virus Trial in Puerto Rico, United States (Velpatasvir, Placebo)
Completed
- Chronic Hepatitis C Virus
- Velpatasvir
- Placebo
-
Costa Mesa, California
- +9 more
Dec 11, 2020
Direct Acting Anti-Viral's In Chronic HCV Patients
Completed
- Safety Issues
-
Faisalabad, Punjab, PakistanLiver Center Faisalabad
Dec 10, 2020
Chronic Hepatitis C, Chronic Hepatitis B Trial in Beijing (Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir)
Recruiting
- Chronic Hepatitis C
- Chronic Hepatitis B
- Tenofovir Alafenamide 25 MG
- Sofosbuvir / Velpatasvir
-
Beijing, Beijing, ChinaPeking University First Hospital
Aug 2, 2021
Against HCV Based on Direct-acting Antivirals in Real-life
Completed
- Chronic Hepatitis C Infection
- Telaprevir
- +10 more
-
Seville, Andalusia, SpainValme University Hospital
Jun 22, 2022
Hepatitis C Virus Infection Trial in Worldwide (Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir
Terminated
- Hepatitis C Virus Infection
- Sofosbuvir (SOF)
- +3 more
-
Phoenix, Arizona
- +50 more
Jan 25, 2023
Hepatitis C, Cryoglobulinemia Trial in New York (Harvoni, Epclusa)
Completed
- Hepatitis C
- Cryoglobulinemia
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Nov 23, 2020
Hepatitis C Virus Infection Trial in Worldwide (SOF/VEL)
Completed
- Hepatitis C Virus Infection
-
Los Angeles, California
- +26 more
Oct 5, 2020
Hepatitis C Trial in Boston (Sofosbuvir/Velpatasvir Treatment for 14 days)
Withdrawn
- Hepatitis C
- Sofosbuvir/Velpatasvir Treatment for 14 days
-
Boston, MassachusettsMassachusetts General Hospital
Jan 16, 2020
Hepatitis C, Chronic Trial in Kigali (sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir)
Unknown status
- Hepatitis C, Chronic
-
Kigali, RwandaRwanda Military Hospital
Sep 10, 2019
HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence Trial in Regina (Genvoya, Epclusa, Biktarvy)
Unknown status
- HIV-1-infection
- +8 more
- Genvoya
- +2 more
-
Regina, Saskatchewan, CanadaSaskatchewan Health Authority
Dec 23, 2019
Chronic Hepatitis C Trial in Worldwide (SOF/VEL)
Completed
- Chronic Hepatitis C
-
Adelaide, South Australia, Australia
- +21 more
Feb 18, 2020
A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
Recruiting
- Hepatitis C
-
Istanbul, TurkeyCerrahpasa Medical Faculty
Aug 26, 2023
Eliminating HCV Infection Among PWUD
Recruiting
- Hepatitis C, Chronic
- Drug Use
-
Vancouver, British Columbia, CanadaVancouver Infectious Diseases Centre
Jul 22, 2022
HCV Trial in United States (Prophylaxis (P2W), Transmit and Treat (T&T))
Not yet recruiting
- HCV
- Prophylaxis (P2W)
- Transmit and Treat (T&T)
-
New Orleans, Louisiana
- +5 more
Dec 6, 2022